Generic Sutab Availability

Last updated on Apr 10, 2025.

Sutab is a brand name of magnesium sulfate/potassium chloride/sodium sulfate, approved by the FDA in the following formulation(s):

SUTAB (magnesium sulfate; potassium chloride; sodium sulfate - tablet;oral)

Manufacturer: BRAINTREE LABS
Approval date: November 10, 2020
Strength(s): 0.225GM;0.188GM;1.479GM ^[RLD]

Is there a generic version of Sutab available?

No. There is currently no therapeutically equivalent version of Sutab available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sutab. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Patent 10,143,656
Issued: December 4, 2018
Inventor(s): Cleveland; Mark vB. et al.
Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Patent expiration dates:
- August 4, 2037
  ✓
  Drug product
Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Patent 11,033,498
Issued: June 15, 2021
Inventor(s): Cleveland Mark vB. & Dennett & Jr. Edmund V. & Pelham Russell W.
Assignee(s): Braintree Laboratories, Inc.
Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Patent expiration dates:
- August 4, 2037
  ✓
  Patent use: GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
Solid oral sulfate salt formulations for cleansing a colon and methods of using same
Patent 11,382,864
Issued: July 12, 2022
Inventor(s): Cleveland; Mark vB et al.
Assignee(s): Braintree Laboratories, Inc. (Braintree, MA)
Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Patent expiration dates:
- August 4, 2037
  ✓
  Patent use: GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY
Solid oral sulfate salt formulations for cleaning a colon and methods of using same
Patent 11,638,697
Issued: May 2, 2023
Inventor(s): Cleveland; Mark vB et al.
Assignee(s): Braintree Laboratories, Inc. (Braintree, MA)
Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
Patent expiration dates:
- August 4, 2037
  ✓
  Drug product

More about Sutab (magnesium sulfate / potassium chloride / sodium sulfate)

Glossary

Term	Definition
Drug Patent	A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity	Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD	A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Drug Status

Availability Prescription only Rx

CSA Schedule* Not a controlled drug N/A

Approval History Drug history at FDA

User Reviews & Ratings

6.3 / 10

127 Reviews

Images

Pill S24 is Sutab sodium sulfate 1.479 g / magnesium sulfate 0.225 g / potassium chloride 0.188 g — Sutab sodium sulfate 1.479 g / magnesium sulfate 0.225 g / potassium chloride 0.188 g (S24)